ChromaDex Corporation (CDXC)
Stock Price:
$4.80 USD
-0.05 (-1.03%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
295.80M |
| Revenue (ttm) |
54.77M |
| Net Income (ttm) |
-25.67M |
| Shares Out |
61.62M |
| EPS (ttm) |
-0.43 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$4.80 |
| Previous Close |
$4.85 |
| Change ($) |
-0.05 |
| Change (%) |
-1.03% |
| Day's Open |
4.83 |
| Day's Range |
4.79 - 4.87 |
| Day's Volume |
148,316 |
| 52-Week Range |
2.50 - 5.80 |
More Stats
| Market Cap |
295.80M |
| Enterprise Value |
278.22M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
61.62M |
| Float |
43.38M |
| EPS (basic) |
-0.43 |
| EPS (diluted) |
-0.43 |
| FCF / Share |
-0.26 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.25M |
| Short Ratio |
7.10 |
| Short % of Float |
4.49% |
| Beta |
1.63 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
5.40 |
| PB Ratio |
13.62 |
| Revenue |
54.77M |
| Operating Income |
-25.33M |
| Net Income |
-25.67M |
| Free Cash Flow |
-15.69M |
| Net Cash |
17.58M |
| Net Cash / Share |
0.29 |
| Gross Margin |
47.05% |
| Operating Margin |
-46.24% |
| Profit Margin |
-46.90% |
| FCF Margin |
-28.64% |
| ROA |
-34.85% |
| ROE |
-139.78% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$7.10*
(47.92% upside)
Low
6.00
Current: $4.80
High
8.50
Target: 7.10
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 46.29 | 31.56 | 21.20 | 21.66 | 17.88 | 15.31 | 10.16 | 11.61 | 8.11 | 7.57 |
| Revenue Growth | 46.69% | 48.85% | -2.14% | 21.13% | 16.79% | 50.71% | -12.48% | 43.12% | 7.22% | - |
| Gross Profit | 25.77 | 16.06 | 10.48 | 10.39 | 7.53 | 5.33 | 3.13 | 2.28 | 2.47 | 2.94 |
| Operating Income | -31.30 | -33.24 | -16.38 | -2.91 | -2.07 | -5.19 | -4.34 | -11.64 | -7.86 | -2.02 |
| Net Income | -32.15 | -33.32 | -11.38 | -2.93 | -2.77 | -5.39 | -4.42 | -11.66 | -7.89 | -2.05 |
| Shares Outstanding | 57.06 | 55.01 | 44.60 | 37.29 | 35.88 | 35.49 | 33.33 | 30.09 | 22.77 | 16.08 |
| Earnings Per Share | -0.56 | -0.61 | -0.26 | -0.08 | -0.08 | -0.15 | -0.12 | -0.39 | -0.36 | -0.12 |
| Operating Cash Flow | -20.44 | -20.91 | -9.80 | -2.94 | -2.11 | -2.58 | -3.91 | -10.12 | -4.10 | -2.66 |
| Capital Expenditures | -0.74 | -1.32 | -1.17 | -1.50 | -0.53 | -0.12 | -0.14 | -0.02 | -0.15 | -0.17 |
| Free Cash Flow | -21.18 | -22.23 | -10.97 | -4.44 | -2.64 | -2.70 | -4.04 | -10.14 | -4.25 | -2.83 |
| Cash & Equivalents | 18.81 | 22.62 | 45.66 | 2.02 | 5.61 | 4.02 | 2.26 | 0.55 | 0.46 | 2.26 |
| Total Debt | 1.72 | 0.31 | 0.51 | 0.60 | 5.54 | 2.77 | 0.42 | 0.23 | 0.24 | 0.28 |
| Net Cash / Debt | 17.09 | 22.31 | 45.16 | 1.42 | 0.07 | 1.25 | 1.84 | 0.33 | 0.22 | 1.98 |
| Assets | 40.25 | 42.23 | 62.72 | 19.75 | 18.75 | 11.52 | 8.99 | 9.03 | 6.27 | 6.51 |
| Liabilities | 19.80 | 15.05 | 8.89 | 9.78 | 13.47 | 7.52 | 3.32 | 5.04 | 3.71 | 1.57 |
| Book Value | 20.45 | 27.18 | 53.83 | 9.97 | 5.27 | 4.00 | 5.67 | 3.99 | 2.56 | 4.94 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
ChromaDex Corporation |
| Country |
United States |
| Employees |
110 |
| CEO |
Robert N. Fried |
Stock Information
| Ticker Symbol |
CDXC |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CDXC |
Description
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is headquartered in Los Angeles, California.